Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025413 · ClinicalTrials.gov registry record · NA
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02025413 is a NA study that has completed, run by Duke University. The registered enrollment target is 46 participants.
The verdict
NCT02025413, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based). The primary objective of each comparative cohort (second stage, prostate cancer) is to compare the non-detection rate of circulating tumor cells between the standard and novel methods.
Interventions
- DEVICE Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025413
The ClinicalTrials.gov registry entry for NCT02025413 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based) is the first listed.
NCT02025413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025413 about?
NCT02025413 is a clinical study titled "Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method". The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be captured using a novel mesenchymal-marker based ferrofluid (N-cadherin or...
What is the current status of trial NCT02025413?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02025413?
The interventions under investigation include: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based) (DEVICE).
Who is sponsoring clinical trial NCT02025413?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.